文献速递神经肿瘤

伏立诺他与异维A酸联合化疗治疗年幼胚胎性脑肿瘤患儿:儿童脑肿瘤联盟(PBTC-026)报告

Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
PubMed 文献 · Neuro Oncol · 2022-01-01

PBTC-026是一项前瞻性多中心临床试验,纳入31例年龄<48个月的新诊断中枢神经系统胚胎性肿瘤患儿,评估在强化细胞毒化疗基础上加入伏立诺他与异维A酸的可行性与安全性。24/31例在预设98天可行窗口内完成诱导治疗,全组5年无进展生存(PFS)为55±15、总生存(OS)为61±13。作者认为将两药纳入强化化疗方案安全可行,并认为需进一步研究确定疗效。

要点

  • 31例<48个月中枢神经系统胚胎性肿瘤患儿接受伏立诺他、异维A酸联合强化化疗。
  • 24/31例在预设98天可行窗口内完成诱导治疗。
  • 全组5年PFS为55±15、OS为61±13。

核心结论

  • 将伏立诺他与异维A酸纳入强化化疗方案是安全且可行的。
  • 作者认为需进一步研究以确定该高危患者群体中的疗效。

研究设计与样本

  • PBTC-026为前瞻性多中心临床试验,纳入年龄<48个月的新诊断中枢神经系统胚胎性肿瘤患儿。
  • 治疗包括3个21天诱导周期(伏立诺他、异维A酸、顺铂、长春新碱、环磷酰胺、依托泊苷)、3个28天巩固周期(卡铂、塞替派后干细胞 rescue)及12个28天维持周期(伏立诺他、异维A酸)。
  • M0髓母细胞瘤患者在巩固治疗后接受局灶放疗,分子分型采用DNA甲基化芯片。

主要发现

  • 31例患者中位年龄26个月(范围6–46),19例(61%)为男性。
  • 诊断为髓母细胞瘤20例,幕上中枢神经系统胚胎性肿瘤11例。
  • 24/31例在预设98天可行窗口内完成诱导治疗。
  • 全部31例的5年无进展生存(PFS)为55±15,总生存(OS)为61±13。
  • 5年PFS:group 3髓母细胞瘤(n=12)为42±13,SHH髓母细胞瘤(n=5)为80±25,多层菊形团胚胎性肿瘤(ETMR,n=6)为33±19。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Embryonal tumors of the CNS are the most common malignant tumors occurring in the first years of life. This study evaluated the feasibility and safety of incorporating novel non-cytotoxic therapy with vorinostat and isotretinoin to an intensive cytotoxic chemotherapy backbone. METHODS: PBTC-026 was a prospective multi-institutional clinical trial for children <48 months of age with newly diagnosed embryonal tumors of the CNS. Treatment included three 21-day cycles of induction therapy with vorinostat and isotretinoin, cisplatin, vincristine, cyclophosphamide, and etoposide; three 28-day cycles of consolidation therapy with carboplatin and thiotepa followed by stem cell rescue; and twelve 28-day cycles of maintenance therapy with vorinostat and isotretinoin. Patients with M0 medulloblastoma (MB) received focal radiation following consolidation therapy. Molecular classification was by DNA methylation array. RESULTS: Thirty-one patients with median age of 26 months (range 6-46) received treatment on study; 19 (61%) were male. Diagnosis was MB in 20 and supratentorial CNS embryonal tumor in 11. 24/31 patients completed induction therapy within a pre-specified feasibility window of 98 days. Five-year progression-free survival (PFS) and overall survival (OS) for all 31 patients were 55 ± 15 and 61 ± 13, respectively. Five-year PFS was 42 ± 13 for group 3 MB (n = 12); 80 ± 25 for SHH MB (n = 5); 33 ± 19 for embryonal tumor with multilayered rosettes (ETMR, n = 6). CONCLUSION: It was safe and feasible to incorporate vorinostat and isotretinoin into an intensive chemotherapy regimen. Further study to define efficacy in this high-risk group of patients is warranted.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Leary SES, Kilburn L, Geyer JR, et al. Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro Oncol. 2022. PMID: 34935967. doi:10.1093/neuonc/noab293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。